{"content":"<li class=\"n-box-item date-title\" data-end=\"1500523199\" data-start=\"1500436800\" data-txt=\"Monday, December 23, 2019\">Wednesday, July 19, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3279705\" data-ts=\"1500507564\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLXT\" target=\"_blank\">CLXT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279705-cellectis-calyxt-prices-ipo-8-bottom-of-reduced-price-range\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectis&#39; Calyxt prices IPO at $8, bottom of reduced price range</a></h4><ul>   <li>Cellectis (<a href=\"http://seekingalpha.com/symbol/CLLS\" target=\"_blank\">CLLS</a> <font color='red'>-3.3%</font>) and Calyxt (NASDAQ:<a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a>) have <a href=\"https://seekingalpha.com/pr/16891440-cellectis-s-calyxt-announces-pricing-56_0-million-initial-public-offering\" target=\"_blank\">priced Calyxt's initial public offering</a> at $8/share, well below a previously expected range of $15-$18.</li>    <li>The company <a href=\"https://seekingalpha.com/news/3279579-cellectis-ag-unit-calyxt-cuts-price-ipo\" target=\"_blank\">trimmed the range to $8-$10</a> earlier. The offering was upsized by nearly a million shares, to 7M, meaning a raise of $56M. Shares should begin trading on Nasdaq under the CLXT symbol tomorrow.</li>    <li>Underwriters have a 30-day option to buy up to an additional 1.05M shares at the IPO price.</li>    <li>After the offering, Cellectis will own about 83.1% of Calyxt's outstanding shares (79.9% if the greenshoe option is fully exercised).</li>    <li>Joint book-runners are Citigroup, Jefferies and Wells Fargo Securities.</li><li><strong>Update</strong>: The IPO was priced at $8. Shares opened at $9.50 on July 20.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279705\" data-linked=\"Cellectis&#39; Calyxt prices IPO at $8, bottom of reduced price range\" data-tweet=\"$CLXT $CLXT $CLLS - Cellectis&#39; Calyxt prices IPO at $8, bottom of reduced price range https://seekingalpha.com/news/3279705-cellectis-calyxt-prices-ipo-8-bottom-of-reduced-price-range?source=tweet\" data-url=\"https://seekingalpha.com/news/3279705-cellectis-calyxt-prices-ipo-8-bottom-of-reduced-price-range\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279699\" data-ts=\"1500504120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AA\" target=\"_blank\">AA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279699-alcoa-slides-after-tightening-full-year-ebitda-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alcoa slides after tightening full-year EBITDA guidance</a></h4><ul>     <li>Alcoa (NYSE:<a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a>) <font color='red'>-2.6%</font>&nbsp;AH despite beating <a href=\"https://seekingalpha.com/news/3279615-alcoa-beats-0_02-beats-revenue\" target=\"_blank\">Q2 earnings</a> estimates, maintaining solid profitability despite lower alumina pricing.</li>     <li>But AA&nbsp;tightens its outlook for FY 2017 adjusted EBITDA to $2.1B-$2.2B from an earlier $2.1B-$2.3B, and now expects negative $50M in net performance for the full year, citing higher input costs driven by strength in the global aluminum market.</li>     <li>For Q2, adjusted EBITDA totaled $483M, down 9% Q/Q, mainly due to lower alumina prices, which rebounded late in the quarter.</li>     <li>AA raises its 2017 forecast for global aluminum demand growth to 4.75%-5.25%, up from a prior outlook of 4.5%-5%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279699\" data-linked=\"Alcoa slides after tightening full-year EBITDA guidance\" data-tweet=\"$AA - Alcoa slides after tightening full-year EBITDA guidance https://seekingalpha.com/news/3279699-alcoa-slides-after-tightening-full-year-ebitda-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3279699-alcoa-slides-after-tightening-full-year-ebitda-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279698\" data-ts=\"1500502651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BG\" target=\"_blank\">BG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279698-bunge-to-cut-costs-restructure-in-response-to-weak-ag-markets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bunge to cut costs, restructure in response to weak ag markets</a></h4><ul>     <li>Bunge (NYSE:<a href='https://seekingalpha.com/symbol/BG' title='Bunge Limited'>BG</a>) <font color='red'>-3.4%</font> AH after saying it expects \"<a href=\"https://seekingalpha.com/pr/16891194-bunge-details-250-million-competitiveness-program-provides-update-second-quarter-performance\" target=\"_blank\">modestly profitable</a>\" Q2 earnings but below the low end of the range of analyst estimates, primarily driven by challenging global agribusiness market conditions.</li>     <li>In response to the tough conditions, BG says it plans to reduce 2018 capex to $650M from a previously announced $750M and cut overhead costs by ~$250M by 2019 while restructuring its global operations.</li>     <li>BG&nbsp;says Q2 market conditions were \"driven by unprecedented farmer retention in South America, which pressured margins throughout the chain,\" but increased farmer pricing early in July and continued strong demand should bring \"much improved\" agribusiness conditions in H2.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279698\" data-linked=\"Bunge to cut costs, restructure in response to weak ag markets\" data-tweet=\"$BG - Bunge to cut costs, restructure in response to weak ag markets https://seekingalpha.com/news/3279698-bunge-to-cut-costs-restructure-in-response-to-weak-ag-markets?source=tweet\" data-url=\"https://seekingalpha.com/news/3279698-bunge-to-cut-costs-restructure-in-response-to-weak-ag-markets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279693\" data-ts=\"1500501726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CKEC\" target=\"_blank\">CKEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279693-amc-drops-barclays-downgrades-on-china-risks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMC drops as Barclays downgrades on China risks</a></h4><ul>   <li>AMC Entertainment closed <font color='red'>down 1.2%</font> today after a <a href=\"https://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+AMC+Entertainment+%28AMC%29+to+Equalweight/13108999.html\" target=\"_blank\">downgrade to Equal Weight</a> from Overweight at Barclays.</li>    <li>Analyst Kannan Venkateshwar says the company faces a risk in China's blocking of bank funds for AMC parent Dalian Wanda, and it's tough to defend the stock without visibility into that issue.</li>    <li>Also, as part of its merger with Carmike Cinemas (NASDAQ:<a href='https://seekingalpha.com/symbol/CKEC' title='Carmike Cinemas, Inc.'>CKEC</a>), AMC will need to divest shares in ad firm National CineMedia (<a href=\"http://seekingalpha.com/symbol/NCMI\" target=\"_blank\">NCMI</a> <font color='green'>+6%</font>) in a short time frame: to a 4.99% stake from about 17% today through 2019, which could expose it to price risk in NCMI.</li>    <li>There's few positive catalysts ahead, which puts a ceiling on upside, though downside may be limited after a recent decline (AMC is <font color='red'>down 34.7%</font> in the past three months; NCMI is <font color='red'>down 40.6%</font> in that same time frame).</li>    <li>Venkateshwar reduced the firm's price target on AMC to $25 from $31, still 26% upside from today's lower price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279693\" data-linked=\"AMC drops as Barclays downgrades on China risks\" data-tweet=\"$CKEC $CKEC $NCMI - AMC drops as Barclays downgrades on China risks https://seekingalpha.com/news/3279693-amc-drops-barclays-downgrades-on-china-risks?source=tweet\" data-url=\"https://seekingalpha.com/news/3279693-amc-drops-barclays-downgrades-on-china-risks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279683\" data-ts=\"1500500476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRW\" target=\"_blank\">CHRW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279683-c-h-robinsonminus-8-q2-hurt-truckload-margin-compression\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">C.H. Robinson -8% as Q2 hurt by truckload margin compression</a></h4><ul>     <li>C.H. Robinson (NASDAQ:<a href='https://seekingalpha.com/symbol/CHRW' title='C.H. Robinson Worldwide Inc.'>CHRW</a>) <font color='red'>-8.2%</font>&nbsp;AH after <a href=\"https://seekingalpha.com/news/3279628-c-h-robinson-worldwide-misses-0_12-beats-revenue\" target=\"_blank\">Q2 earnings</a> came in well below Wall Street expectations, with the transportation and logistics company saying results were hurt significantly by truckload margin compression.</li>     <li>Q2 total net revenues fell 3.4%, reflecting last September's acquisition of APC Logistics, while total operating expenses rose 8.7% Y/Y.</li><li>CHRW says purchased       transportation costs increased significantly during the quarter, while       much of its customer pricing is committed at relatively flat prices.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279683\" data-linked=\"C.H. Robinson -8% as Q2 hurt by truckload margin compression\" data-tweet=\"$CHRW - C.H. Robinson -8% as Q2 hurt by truckload margin compression https://seekingalpha.com/news/3279683-c-h-robinsonminus-8-q2-hurt-truckload-margin-compression?source=tweet\" data-url=\"https://seekingalpha.com/news/3279683-c-h-robinsonminus-8-q2-hurt-truckload-margin-compression\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279680\" data-ts=\"1500500110\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279680-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/HPJ' title='Highpower International, Inc.'>HPJ</a> <font color='green'>+22.0%</font>. <a href='https://seekingalpha.com/symbol/AVA' title='Avista Corporation'>AVA</a> <font color='green'>+19.3%</font>. <a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+14.3%</font>. <a href='https://seekingalpha.com/symbol/PLXS' title='Plexus Corp.'>PLXS</a> <font color='green'>+6.4%</font>. <a href='https://seekingalpha.com/symbol/KMI' title='Kinder Morgan, Inc.'>KMI</a> <font color='green'>+4.4%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/PTC' title='PTC Inc.'>PTC</a> <font color='red'>-11.7%</font>. <a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a> <font color='red'>-8.9%</font>. <a href='https://seekingalpha.com/symbol/CHRW' title='C.H. Robinson Worldwide Inc.'>CHRW</a> <font color='red'>-8.2%</font>. <a href='https://seekingalpha.com/symbol/WES' title='Western Gas Partners, L.P.'>WES</a> <font color='red'>-4.7%</font>. <a href='https://seekingalpha.com/symbol/SPN' title='Superior Energy Services, Inc.'>SPN</a> <font color='red'>-3.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279680\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$HPJ $AVA $SRPT - After Hours Gainers / Losers https://seekingalpha.com/news/3279680-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3279680-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279679\" data-ts=\"1500499165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMCX\" target=\"_blank\">AMCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279679-moodys-boosts-senior-secured-rating-on-amc-networks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moody&#39;s boosts senior secured rating on AMC Networks</a></h4><ul>   <li>Moody's has given a <a href=\"https://www.moodys.com/research/Moodys-assigns-Ba3-rating-to-AMC-Networks-proposed-notes-issuance--PR_369941?WT.mc_id=AM~WWFob29fRmluYW5jZV9TQl9SYXRpbmcgTmV3c19BbGxfRW5n~20170719_PR_369941\" target=\"_blank\">Ba3 rating</a> to a proposed $500M debt issuance from AMC Networks (<a href=\"http://seekingalpha.com/symbol/AMCX\" target=\"_blank\">AMCX</a> <font color='green'>+4%</font>), and a Baa2 rating to its new secured bank debt refinancing.</li>    <li>Its outlook on the company is stable.</li>    <li>The $500M notes are guaranteed on a senior unsecured basis, subordinated to the company's senior secure credit facility.</li>    <li>That senior secured facility consists of a $500M revolving credit facility and a $750M term loan A.</li>    <li>\"Since the new debt issuance is leverage neutral this transaction doesn't impact the company's Ba2 CFR or Ba2-PD probability of default rating,\" Moody's says. \"However, due to the expected shift between secured and unsecured debt within AMC's capital structure, the potential additional loss absorption cushion for the secured debt provided by these new notes lifts the company's senior secured rating up one notch to Baa2 from Baa3.\"</li>    <li>After hours: <a href='https://seekingalpha.com/symbol/AMCX' title='AMC Networks Inc.'>AMCX</a> <font color='green'>+1.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279679\" data-linked=\"Moody&#39;s boosts senior secured rating on AMC Networks\" data-tweet=\"$AMCX - Moody&#39;s boosts senior secured rating on AMC Networks https://seekingalpha.com/news/3279679-moodys-boosts-senior-secured-rating-on-amc-networks?source=tweet\" data-url=\"https://seekingalpha.com/news/3279679-moodys-boosts-senior-secured-rating-on-amc-networks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279669\" data-ts=\"1500498177\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTC\" target=\"_blank\">PTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279669-ptc-reports-q3-subscription-bookings-down-issues-weak-guidance-shares-down-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTC reports Q3 subscription bookings down, issues weak guidance; shares down 12%</a></h4><ul><li>        PTC (NASDAQ:<a href='https://seekingalpha.com/symbol/PTC' title='PTC Inc.'>PTC</a>) reports Q3 earnings with a revenue beat and in-line EPS but licensing and subscription bookings weren&rsquo;t as rosy.</li><li>               Licensing and subscription bookings were $90M,&nbsp;<font color='red'>down 14%</font>&nbsp;on the prior year&rsquo;s quarter due to &ldquo;sales execution issues&rdquo; in Japan. Subscription bookings were 64% of total bookings, a bit below expectations.&nbsp;</li><li>               Software revenue was $248M,&nbsp;<font color='green'>up 4%&nbsp;</font>on the year, with 87% coming from recurring revenue streams.&nbsp;</li><li>               Cash: OCF was $74M and FCF was $69M. PTC ended the quarter with $311M in cash and equivalents with $712M in total debt.&nbsp;</li><li>               Q4 guidance: revenue expected between $303M and $308M, below the $308.99 consensus, and EPS between $0.33 and $0.38, which beats $0.37 consensus on the high end.&nbsp;</li><li>               FY17 guidance: revenue expected between $1.16B and $1.17B, which matches consensus on the high end. EPS estimated between $1.17 and $1.22 compared to $1.20 consensus.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16891189-ptc-announces-third-quarter-fiscal-2017-results\" target=\"_blank\">Press release</a>&nbsp;</li><li>PTC shares are&nbsp;<font color='red'>down 12.17%</font>&nbsp;aftermarket.&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279610-ptc-eps-line-beats-revenue\" target=\"_blank\">PTC EPS in-line, beats on revenue</a> (July 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279669\" data-linked=\"PTC reports Q3 subscription bookings down, issues weak guidance; shares down 12%\" data-tweet=\"$PTC - PTC reports Q3 subscription bookings down, issues weak guidance; shares down 12% https://seekingalpha.com/news/3279669-ptc-reports-q3-subscription-bookings-down-issues-weak-guidance-shares-down-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3279669-ptc-reports-q3-subscription-bookings-down-issues-weak-guidance-shares-down-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279658\" data-ts=\"1500497421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVA\" target=\"_blank\">AVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279658-avista-to-be-bought-hydro-one-for-53-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avista to be bought by Hydro One for $53/share</a></h4><ul>     <li>Avista (NYSE:<a href='https://seekingalpha.com/symbol/AVA' title='Avista Corporation'>AVA</a>) <font color='green'>+17.7%</font>&nbsp;AH after <a href=\"https://seekingalpha.com/pr/16891321-hydro-one-acquire-avista-create-growing-north-american-utility-leader-c-31_2-billion\" target=\"_blank\">agreeing to be acquired</a> by Canadian electricity transmission and distribution company Hydro One (<a href='https://seekingalpha.com/symbol/HRNNF' title='Hydro One Ltd'>OTC:HRNNF</a>) for US$53/share, a 24% premium over yesterday's closing price.</li>     <li>The C$6.7B (US$5.3B) deal would create a North American leader in regulated electricity and natural gas business with more than C$32.2B (US$25.4B) in combined  assets.</li>     <li>AVA will continue to operate as a standalone utility in the U.S. Pacific Northwest, with its own board, management team and employees remaining in place.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279658\" data-linked=\"Avista to be bought by Hydro One for $53/share\" data-tweet=\"$AVA $AVA $HRNNF - Avista to be bought by Hydro One for $53/share https://seekingalpha.com/news/3279658-avista-to-be-bought-hydro-one-for-53-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3279658-avista-to-be-bought-hydro-one-for-53-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279654\" data-ts=\"1500496823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMI\" target=\"_blank\">KMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279654-kinder-morgan-pledges-60-dividend-hike-next-year-rising-to-1-share-in-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kinder Morgan pledges 60% dividend hike next year, rising to $1/share in &#39;19</a></h4><ul>     <li>Kinder Morgan (NYSE:<a href='https://seekingalpha.com/symbol/KMI' title='Kinder Morgan, Inc.'>KMI</a>) <font color='green'>+3.7%</font>&nbsp;AH after announcing plans for an $0.80/share dividend for 2018, a 60% increase, beginning with next year's Q1, and rising to $1.00/share in 2019 and $1.25 in 2020.</li>     <li>For the rest of this year, KMI expects to declare dividends of $0.50/share and use cash in excess of dividend payments to fully fund growth investments.</li>     <li>Also in its <a href=\"https://seekingalpha.com/news/3279640-kinder-morgan-eps-line-beats-revenue\" target=\"_blank\">Q2 report</a>, KMI announces a $2B share buyback program, representing ~5% of current market cap.</li><li>As a result of the IPO of Canadian assets, KMI now expects to end the year with a net       debt-to-Adjusted EBITDA ratio of ~5.2x, growth capital       investment of $3.1B and distributable cash flow less than 1% below budget.</li>     <li>Current project backlog is $12.2B, up       from $11.7B at the end of Q1.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279654\" data-linked=\"Kinder Morgan pledges 60% dividend hike next year, rising to $1/share in &#39;19\" data-tweet=\"$KMI - Kinder Morgan pledges 60% dividend hike next year, rising to $1/share in &#39;19 https://seekingalpha.com/news/3279654-kinder-morgan-pledges-60-dividend-hike-next-year-rising-to-1-share-in-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3279654-kinder-morgan-pledges-60-dividend-hike-next-year-rising-to-1-share-in-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>83&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279651\" data-ts=\"1500496557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMUS\" target=\"_blank\">TMUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279651-t-mobile-resumes-up-3_8-after-healthy-q2-beat-strong-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T-Mobile resumes up 3.8% after healthy Q2 beat, strong guidance</a></h4><ul>   <li>T-Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) has resumed trading after its 4 p.m. halt, <font color='green'>up 3.8%</font>, as it starts its <a href=\"https://www.youtube.com/watch?v=Xd2XSosGOP8\" target=\"_blank\">earnings call</a> after <a href=\"https://seekingalpha.com/news/3279622-record-revenues-boost-t-mobile-substantial-q2-beat\" target=\"_blank\">blowing out estimates</a> for its second quarter.</li>    <li>The company's boosting full-year guidance on branded postpaid net adds, to the range of 3M-3.6M from a previous 2.8M-3.5M. It's also raising guidance or EBITDA, to $10.5B-$10.9B from a previous $10.4B-$10.8B (and vs. consensus for $10.5B).</li>    <li>Leasing revenues for 2017 are now forecast at $0.85B-$0.95B, up from previous $0.8B-$0.9B.</li>    <li>It's maintaining guidance on $4.8B-$5.1B for cash purchases of property and equipment and expects to land on the high side there.</li>    <li>Three-year compound annual growth rate for cash from operations is still expected at 15-18%, and for free cash flow at 45-48%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279611-t-mobile-us-beats-0_29-beats-revenue\" target=\"_blank\">T-Mobile US beats by $0.29, beats on revenue</a> (Jul. 19 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279651\" data-linked=\"T-Mobile resumes up 3.8% after healthy Q2 beat, strong guidance\" data-tweet=\"$TMUS - T-Mobile resumes up 3.8% after healthy Q2 beat, strong guidance https://seekingalpha.com/news/3279651-t-mobile-resumes-up-3_8-after-healthy-q2-beat-strong-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3279651-t-mobile-resumes-up-3_8-after-healthy-q2-beat-strong-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279649\" data-ts=\"1500496514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGLS\" target=\"_blank\">RGLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279649-regulus-readies-equity-offering-shares-off-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regulus readies equity offering; shares off 3% after hours</a></h4><ul><li>Regulus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a>) <a href=\"https://seekingalpha.com/pr/16891193-regulus-announces-commencement-public-offering-common-stock\" target=\"_blank\">launches </a>a public offering of common stock. Price, volume and terms have yet to be announced. Net proceeds will fund clinical trials, capex, working capital and general corporate purposes.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279649\" data-linked=\"Regulus readies equity offering; shares off 3% after hours\" data-tweet=\"$RGLS - Regulus readies equity offering; shares off 3% after hours https://seekingalpha.com/news/3279649-regulus-readies-equity-offering-shares-off-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3279649-regulus-readies-equity-offering-shares-off-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279640\" data-ts=\"1500496177\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMI\" target=\"_blank\">KMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279640-kinder-morgan-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kinder Morgan EPS in-line, beats on revenue</a></h4><ul><li>Kinder Morgan (NYSE:<a href='https://seekingalpha.com/symbol/KMI' title='Kinder Morgan, Inc.'>KMI</a>): Q2 EPS of $0.15 in-line.</li><li>Revenue of $3.37B (+7.3% Y/Y) <font color='green'>beats by $270M</font>.</li><li>Shares <font color='green'>+3.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16891217-kinder-morgan-announces-expected-60-percent-dividend-increase-2018-projects-25-percent-annual'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279640\" data-linked=\"Kinder Morgan EPS in-line, beats on revenue\" data-tweet=\"$KMI - Kinder Morgan EPS in-line, beats on revenue https://seekingalpha.com/news/3279640-kinder-morgan-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279640-kinder-morgan-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279638\" data-ts=\"1500496034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AERI\" target=\"_blank\">AERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279638-aerie-pharmas-eye-drop-roclatan-safe-in-12-month-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aerie Pharma&#39;s eye drop Roclatan safe in 12-month study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16891180-aerie-pharmaceuticals-reports-positive-roclatan-netarsudil-latanoprost-ophthalmic-solution\" target=\"_blank\">Results </a>from the 12-month Mercury 1 study demonstrated that Aerie Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/AERI' title='Aerie Pharmaceuticals, Inc.'>AERI</a>) Roclatan (netarsudil/latanoprost ophthalmic solution) was safe over an extended time frame in glaucoma patients. The results were consistent with what was observed in the 90-day efficacy period. No new adverse events developed following day 90.</li><li>The data will be included in the company's global regulatory applications. The FDA submission should be made in H1 2018.</li><li>Management will host a conference call today at 5:00 pm ET to discuss the results.</li><li>Shares are off a fraction after hours.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3269704-aeris-roclatan-successful-late-stage-study-eye-drop-roclatan-shares-28-percent-hours\" target=\"_blank\">Aeri's Roclatan successful in late-stage study of eye drop Roclatan; shares up 28% after hours</a> (May 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279638\" data-linked=\"Aerie Pharma&#39;s eye drop Roclatan safe in 12-month study\" data-tweet=\"$AERI - Aerie Pharma&#39;s eye drop Roclatan safe in 12-month study https://seekingalpha.com/news/3279638-aerie-pharmas-eye-drop-roclatan-safe-in-12-month-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3279638-aerie-pharmas-eye-drop-roclatan-safe-in-12-month-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279636\" data-ts=\"1500495969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279636-qualcomm-beats-q2-estimates-expects-continued-royalty-damage-from-apple\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm beats Q2 estimates, expects continued royalty damage from Apple</a></h4><ul><li>           Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) reports Q3 results with beats on revenue and EPS but omits some metrics and expects royalty payments to continue suffering from the company's legal battle with Apple.  </li><li> Segment revenues: QCT: $4.1B, up 5% on the year and 10% on the quarter; QTL: $1.2B, down 42% on the year and 48% on the quarter. </li><li> Qualcomm has stripped several metrics from the QTL revenue reporting and from the guidance estimates because of the royalty payment withholding from Apple and its contract manufacturers, which Qualcomm doesn&rsquo;t expect to end soon.  </li><li> Stripped metrics include total reported device sales, device shipment estimates, and average selling prices.&nbsp; </li><li>        Cash: Qualcomm ended the quarter with $37.8B in cash and equivalents.&nbsp;</li><li>               NXP acquisition update: Qualcomm still hopes to close out the deal this year subject to regulatory approvals.&nbsp;</li><li>           Q4 guidance: Qualcomm expects EPS between $0.75 and $0.85 compared to the $0.91 consensus. Revenue estimated between $5.4B and $6.2B compared to $5.26B consensus. </li><li> <a href=\"https://seekingalpha.com/pr/16891202-qualcomm-earnings-release-available-companys-investor-relations-website\" target=\"_blank\">Press Release&nbsp;</a> </li><li>                  Qualcomm shares are&nbsp;<font color='red'>down 3.03%</font>&nbsp;aftermarket.&nbsp;&nbsp;<br /> </li><li>Previously: <a href=\"https://seekingalpha.com/news/3279599-qualcomm-beats-0_02-beats-revenue\" target=\"_blank\">Qualcomm beats by $0.02, beats on revenue</a> (July 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279636\" data-linked=\"Qualcomm beats Q2 estimates, expects continued royalty damage from Apple\" data-tweet=\"$QCOM - Qualcomm beats Q2 estimates, expects continued royalty damage from Apple https://seekingalpha.com/news/3279636-qualcomm-beats-q2-estimates-expects-continued-royalty-damage-from-apple?source=tweet\" data-url=\"https://seekingalpha.com/news/3279636-qualcomm-beats-q2-estimates-expects-continued-royalty-damage-from-apple\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279623\" data-ts=\"1500495402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URI\" target=\"_blank\">URI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279623-united-rentals-beats-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Rentals beats by $0.08, beats on revenue</a></h4><ul><li>United Rentals (NYSE:<a href='https://seekingalpha.com/symbol/URI' title='United Rentals, Inc.'>URI</a>): Q2 EPS of $2.37 <font color='green'>beats by $0.08</font>.</li><li>Revenue of $1.6B (+12.7% Y/Y) <font color='green'>beats by $40M</font>.</li><li>Shares <font color='green'>+5.2%</font>.</li><li><a href='https://seekingalpha.com/pr/16891241-united-rentals-announces-second-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279623\" data-linked=\"United Rentals beats by $0.08, beats on revenue\" data-tweet=\"$URI - United Rentals beats by $0.08, beats on revenue https://seekingalpha.com/news/3279623-united-rentals-beats-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279623-united-rentals-beats-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279619\" data-ts=\"1500495319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279619-sarepta-q2-exondys-51-sales-35m-net-loss-63m-shares-ahead-10-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta Q2 Exondys 51 sales $35M; net loss: $63M; shares ahead 10% after hours</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) <a href=\"https://seekingalpha.com/pr/16891192-sarepta-therapeutics-announces-second-quarter-2017-financial-results-recent-corporate\" target=\"_blank\">Q2 results</a> ($M): EXONDYS 51 Sales: 35.0; Net Loss: (63.0) (-1.1%); Non-GAAP Net Loss: (25.3) (+53.8%); Loss/Share: (1.15) (+14.8%); Non-GAAP Loss/Share: (0.46) (+61.3%); Quick Assets: 301.7 (-8.4%).</li><li>Key catalysts for H2: release of 4053-101 dystrophin data; potentially up to seven DMD therapies will be in clinical development.</li><li><strong>2017 Guidance</strong>: EXONDYS 51 Sales: $125M - 130M.</li><li>Shares are up 10% after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279619\" data-linked=\"Sarepta Q2 Exondys 51 sales $35M; net loss: $63M; shares ahead 10% after hours\" data-tweet=\"$SRPT - Sarepta Q2 Exondys 51 sales $35M; net loss: $63M; shares ahead 10% after hours https://seekingalpha.com/news/3279619-sarepta-q2-exondys-51-sales-35m-net-loss-63m-shares-ahead-10-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3279619-sarepta-q2-exondys-51-sales-35m-net-loss-63m-shares-ahead-10-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279607\" data-ts=\"1500494866\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOD\" target=\"_blank\">GOOD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279607-capital-raise-from-gladstone-commercial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capital raise from Gladstone Commercial</a></h4><ul><li>The size of the <a href=\"https://seekingalpha.com/pr/16891190-gladstone-commercial-corporation-announces-common-stock-offering\" target=\"_blank\">common share sale</a> isn't given. Janney, D.A. Davidson, Nomura, and Wunderlich are underwriting.</li><li><a href='https://seekingalpha.com/symbol/GOOD' title='Gladstone Commercial Corporation'>GOOD</a>&nbsp;<font color='green'>+0.7%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3279607\" data-linked=\"Capital raise from Gladstone Commercial\" data-tweet=\"$GOOD - Capital raise from Gladstone Commercial https://seekingalpha.com/news/3279607-capital-raise-from-gladstone-commercial?source=tweet\" data-url=\"https://seekingalpha.com/news/3279607-capital-raise-from-gladstone-commercial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279603\" data-ts=\"1500494804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXP\" target=\"_blank\">AXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279603-american-express-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Express beats by $0.03, beats on revenue</a></h4><ul><li>American Express (NYSE:<a href='https://seekingalpha.com/symbol/AXP' title='American Express Company'>AXP</a>): Q2 EPS of $1.47 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $8.31B (+1.0% Y/Y) <font color='green'>beats by $110M</font>.</li><li>Shares <font color='green'>+1.25%</font>.</li><li><a href='https://seekingalpha.com/pr/16891205-american-express-reports-second-quarter-eps-1_47-reflecting-higher-revenues-strong-credit'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279603\" data-linked=\"American Express beats by $0.03, beats on revenue\" data-tweet=\"$AXP - American Express beats by $0.03, beats on revenue https://seekingalpha.com/news/3279603-american-express-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279603-american-express-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279602\" data-ts=\"1500494780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLXS\" target=\"_blank\">PLXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279602-plexus-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plexus beats by $0.02, beats on revenue</a></h4><ul><li>Plexus (NASDAQ:<a href='https://seekingalpha.com/symbol/PLXS' title='Plexus Corp.'>PLXS</a>): Q3 EPS of $0.74 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $619M (-7.3% Y/Y) <font color='green'>beats by $10.21M</font>.</li><li>Shares <font color='green'>+2%</font>.</li><li><a href='https://seekingalpha.com/pr/16891199-plexus-announces-fiscal-third-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279602\" data-linked=\"Plexus beats by $0.02, beats on revenue\" data-tweet=\"$PLXS - Plexus beats by $0.02, beats on revenue https://seekingalpha.com/news/3279602-plexus-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279602-plexus-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279595\" data-ts=\"1500494586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279595-sarepta-therapeutics-beats-0_45-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta Therapeutics beats by $0.45, beats on revenue</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>): Q2 EPS of -$0.46 <font color='green'>beats by $0.45</font>.</li><li>Revenue of $35M <font color='green'>beats by $12.62M</font>.</li><li>Shares <font color='green'>+11.7%</font>.</li><li><a href='https://seekingalpha.com/pr/16891192-sarepta-therapeutics-announces-second-quarter-2017-financial-results-recent-corporate'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279595\" data-linked=\"Sarepta Therapeutics beats by $0.45, beats on revenue\" data-tweet=\"$SRPT - Sarepta Therapeutics beats by $0.45, beats on revenue https://seekingalpha.com/news/3279595-sarepta-therapeutics-beats-0_45-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279595-sarepta-therapeutics-beats-0_45-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279587\" data-ts=\"1500493005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CODX\" target=\"_blank\">CODX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279587-ipo-co-diagnostics-off-to-weak-start-shares-down-18-from-debut-price\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IPO Co-Diagnostics off to a weak start, shares down 18% from debut price</a></h4><ul><li><a href=\"http://codiagnostics.com/\" target=\"_blank\">Co-Diagnostics</a> (<a href='https://seekingalpha.com/symbol/CODX' title='Co-Diagnostics'>CODX</a> <font color='red'>-0.6%</font>) did not get off to the <a href=\"https://www.sec.gov/Archives/edgar/data/1692415/000147793217003231/codx_s1a.htm\" target=\"_blank\">start </a>it was looking for. Shares are down over 18% from the IPO price of $6. Trading commenced July 12.</li><li>The Bountiful, UT-based molecular diagnostics firm makes and sells reagents used in molecular testing as well as OEM equipment. Its low-cost system can perform tests for tuberculosis, Zika, hepatitis B &amp; C, malaria, dengue and HIV.</li><li><strong>2016 Financials</strong> ($M): Operating Expenses: 1.7 (-14.7%); Net Loss: (1.9) (+5.0%); Cash Flow Ops: (1.3) (+13.3%).</li></ul><div class=\"tiny-share-widget\" data-id=\"3279587\" data-linked=\"IPO Co-Diagnostics off to a weak start, shares down 18% from debut price\" data-tweet=\"$CODX - IPO Co-Diagnostics off to a weak start, shares down 18% from debut price https://seekingalpha.com/news/3279587-ipo-co-diagnostics-off-to-weak-start-shares-down-18-from-debut-price?source=tweet\" data-url=\"https://seekingalpha.com/news/3279587-ipo-co-diagnostics-off-to-weak-start-shares-down-18-from-debut-price\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279588\" data-ts=\"1500493005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JONE\" target=\"_blank\">JONE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279588-jones-energy-says-q2-production-exceeded-high-end-of-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jones Energy says Q2 production exceeded high end of guidance</a></h4><ul>     <li>Jones Energy (<a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+3.6%</font>) is higher after reporting <a href=\"https://seekingalpha.com/pr/16890065-jones-energy-inc-announces-top-decile-meramec-well-results-second-quarter-production\" target=\"_blank\">Q2 production</a> that exceeded the high end of company guidance.</li>     <li>Jones expects Q2 production of 23.8K boe/day, or 2.17M boe, ~10% above the top end of prior guidance of 20.7K-21.7K boe/day, and believes it remains on pace  to achieve FY 2017 production guidance of 20.7K-23K boe/day.</li>     <li>Jones says its first Meramec well achieved in the top 10% of Merge wells, reaching a peak rate of 650  boe/day, and says it deployed its second Merge rig as planned on July 1 and continues to anticipate adding a third rig by year-end</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279588\" data-linked=\"Jones Energy says Q2 production exceeded high end of guidance\" data-tweet=\"$JONE - Jones Energy says Q2 production exceeded high end of guidance https://seekingalpha.com/news/3279588-jones-energy-says-q2-production-exceeded-high-end-of-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3279588-jones-energy-says-q2-production-exceeded-high-end-of-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279583\" data-ts=\"1500491853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPI\" target=\"_blank\">LPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279583-laredo-petroleum-confirms-process-to-sell-stake-in-medallion-pipeline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Laredo Petroleum confirms process to sell stake in Medallion pipeline</a></h4><ul>     <li>Laredo Petroleum (<a href='https://seekingalpha.com/symbol/LPI' title='Laredo Petroleum Holdings, Inc.'>LPI</a> <font color='green'>+12%</font>) confirms it has <a href=\"https://seekingalpha.com/pr/16891133-laredo-petroleum-confirms-process-sell-interest-medallion-pipeline\" target=\"_blank\">started a process to sell</a> its 49% interest in the Medallion-Midland Basin pipeline system in Texas; shares resume trading after a brief halt.</li>     <li>Medallion&rsquo;s Wolfcamp Connector crude oil pipeline consists of 370-plus miles of 10- and 12-inch gathering and mainline pipe, its Red River Gathering System consists of 100 miles of four- to eight-inch gathering pipelines, and the Pecos River&nbsp;Gathering System consists of 11 miles of four- to 10-inch  gathering pipleines.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279583\" data-linked=\"Laredo Petroleum confirms process to sell stake in Medallion pipeline\" data-tweet=\"$LPI - Laredo Petroleum confirms process to sell stake in Medallion pipeline https://seekingalpha.com/news/3279583-laredo-petroleum-confirms-process-to-sell-stake-in-medallion-pipeline?source=tweet\" data-url=\"https://seekingalpha.com/news/3279583-laredo-petroleum-confirms-process-to-sell-stake-in-medallion-pipeline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279575\" data-ts=\"1500490815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279575-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/HQCL' title='Hanwha Q CELLS Co., Ltd.'>HQCL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MRAM' title='Everspin Technologies'>MRAM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/HDP' title='Hortonworks'>HDP</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279575\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$MYSZ $IZEA $HQCL - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3279575-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279575-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279571\" data-ts=\"1500489354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279571-channel-checks-prompt-needham-to-reiterate-buy-on-facebook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Channel checks prompt Needham to reiterate Buy on Facebook</a></h4><ul>   <li>Needham has reiterated its Buy rating on Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='green'>+1.6%</font>), saying channel checks are pointing to <a href=\"http://www.barrons.com/articles/facebook-less-competition-from-snap-as-they-reach-mobile-monopoly-says-needham-1500486233\" target=\"_blank\">better-than-expected ad revenue growth</a> -- particularly as its Instagram is less likely to see real competition from Snap (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color='green'>+2.6%</font>).</li>    <li>&ldquo;We now believe Facebook is becoming the de facto near-monopoly mobile choice for brands and direct response (i.e., lead generation) advertisers,\" writes analyst Laura Martin.</li>    <li>She's boosting Q2 expectations to revenues of $9.18B (vs. consensus expectations for $9.19B) and EPS of $1.09, slightly below Street expectations for $1.11.</li>    <li>Snap, meanwhile, is up nicely today after announcing a <a href=\"https://seekingalpha.com/news/3279398-nbc-news-show-snapchat\" target=\"_blank\">partnership with NBC News</a> (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) to produce a twice-daily newscast, <em>Stay Tuned.</em> NBC will share revenue with Snap from ads sold on the show.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279571\" data-linked=\"Channel checks prompt Needham to reiterate Buy on Facebook\" data-tweet=\"$CMCSA $CMCSA $FB - Channel checks prompt Needham to reiterate Buy on Facebook https://seekingalpha.com/news/3279571-channel-checks-prompt-needham-to-reiterate-buy-on-facebook?source=tweet\" data-url=\"https://seekingalpha.com/news/3279571-channel-checks-prompt-needham-to-reiterate-buy-on-facebook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279570\" data-ts=\"1500489070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMNT\" target=\"_blank\">OMNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279570-omintos-tumble-continues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ominto&#39;s tumble continues</a></h4><ul><li>Uplisted to the Nasdaq in March, the online cash back shopping company through July 1 had&nbsp;<font color='green'>more than quadrupled&nbsp;</font>this year. It's&nbsp;<font color='red'>lost about 50%&nbsp;</font>of its value since.</li><li>\"How Has This Stock Not Been Delisted Yet,\" is the title of <a href=\"http://www.valuewalk.com/2017/07/ominto-inc-omnt-stock-not-delisted-yet/\" target=\"_blank\">an anonymous essay</a> which appeared on ValueWalk yesterday.</li><li><a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a>&nbsp;<font color='red'>-11.8%</font>&nbsp;today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279570\" data-linked=\"Ominto&#39;s tumble continues\" data-tweet=\"$OMNT - Ominto&#39;s tumble continues https://seekingalpha.com/news/3279570-omintos-tumble-continues?source=tweet\" data-url=\"https://seekingalpha.com/news/3279570-omintos-tumble-continues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279566\" data-ts=\"1500488407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBNY\" target=\"_blank\">SBNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279566-signature-bank-lower-after-taxi-medallion-writedown-cap-one-on-watch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Signature Bank lower after taxi medallion writedown; Cap One on watch</a></h4><ul><li>Signature Bank (NASDAQ:<a href='https://seekingalpha.com/symbol/SBNY' title='Signature Bank'>SBNY</a>) in Q2 wrote <a href=\"https://seekingalpha.com/pr/16890176-signature-bank-reports-2017-second-quarter-results\" target=\"_blank\">down each of its </a>NYC taxi medallion loans to a value of about $358K, a hit of about $18M or $0.31 per share (excluding the writedown, EPS of $2.21 met expectations).</li><li>The bank's exposure is now $324.5M, or 80 basis points of assets.</li><li>A bull on the stock, Jefferies' Casey Haire says this is only a step to eliminate the overhang. A further writedown to $250K each would hit tangible book value by another 1.5%.</li><li>At its worst level post-earnings, the stock was&nbsp;<font color='red'>down nearly 5%</font>. It's&nbsp;<font color='red'>off just 1.8%&nbsp;</font>at the moment.</li><li>Betsy Graseck worries about the read-through for Capital One (<a href='https://seekingalpha.com/symbol/COF' title='Capital One Financial Corporation'>COF</a> <font color='red'>-0.4%</font>), and suggests a similar markdown (40%) by that lender would hit Q2 EPS by $0.33, or 18% of analyst estimates. Graseck cautions that she doesn't have any special insight into Cap One's taxi medallion loan portfolio, and this is just back-of-the-envelope stuff. Capital One reports tomorrow after the close.</li><li>Analyst comments via Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279387-signature-bank-eps-line-misses-revenue\" target=\"_blank\">Signature Bank EPS in-line, misses on revenue</a> (July 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279566\" data-linked=\"Signature Bank lower after taxi medallion writedown; Cap One on watch\" data-tweet=\"$SBNY $SBNY $COF - Signature Bank lower after taxi medallion writedown; Cap One on watch https://seekingalpha.com/news/3279566-signature-bank-lower-after-taxi-medallion-writedown-cap-one-on-watch?source=tweet\" data-url=\"https://seekingalpha.com/news/3279566-signature-bank-lower-after-taxi-medallion-writedown-cap-one-on-watch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279559\" data-ts=\"1500487268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279559-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/PDS' title='Precision Drilling Corporation'>PDS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PACD' title='Pacific Drilling SA'>PACD</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a> <font color='green'>+9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279559\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$XCO $ERN $PDS - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3279559-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279559-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279555\" data-ts=\"1500486326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279555-financials-top-5-gainers-losers-of-1-45-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:45 PM</a></h4><ul><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NTRS' title='Northern Trust Corporation'>NTRS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HBHC' title='Hancock Holding Company'>HBHC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/PZN' title='Pzena Investment Management, Inc.'>PZN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NAVI' title='Navient Corp'>NAVI</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279555\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:45 PM\" data-tweet=\"$NTRS $HBHC $PZN - Financials - Top 5 Gainers / Losers as of 1:45 PM https://seekingalpha.com/news/3279555-financials-top-5-gainers-losers-of-1-45-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279555-financials-top-5-gainers-losers-of-1-45-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279551\" data-ts=\"1500485156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRP\" target=\"_blank\">NTRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279551-neurotropes-mid-stage-data-on-alzheimers-candidate-underwhelms-investors-shares-down-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neurotrope&#39;s mid-stage data on Alzheimer&#39;s candidate underwhelms investors; shares down 17%</a></h4><ul><li>Thinly traded nano cap Neurotrope (<a href='https://seekingalpha.com/symbol/NTRP' title='Neurotrope, Inc.'>NTRP</a> <font color='red'>-17.2%</font>) slumps on almost triple normal volume, albeit on only 202K shares, in response to its <a href=\"https://seekingalpha.com/pr/16890925-neurotrope-presents-phase-2-data-assessing-bryostatinminus-1-moderate-severe-alzheimers\" target=\"_blank\">announcement </a>of results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02431468?term=bryostatin&amp;phase=1&amp;draw=1&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> assessing bryostatin-1 in patients with moderate-to-severe Alzheimer's disease &#40;AD&#41;. The data were presented at the Alzheimer's Association International Conference in London.</li><li>The 13-week, randomized, double-blind, placebo-controlled study evaluated the safety, tolerability and efficacy of two doses (20 &micro;g and 40 &micro;g) of bryostatin-1 in 147 AD patients.</li><li>Improvements in a scale called Severe Impairment Battery &#40;SIB&#41;, the primary cognitive endpoint, were observed in the 20 &micro;g arm but not in the 40 &micro;g arm. In addition, patients treated with the higher dose had a higher dropout rate with a higher incidence of treatment-emergent adverse events.</li><li>The company says the lack of signal at the 40 &micro;g dose was not unexpected since the downregulation phase appears to override the initial activation phase, thereby dampening the desired clinical effect.</li><li><a href=\"http://www.brni.org/scientific_research/clinical_trials.aspx\" target=\"_blank\">Bryostatin</a>, an activator of an enzyme called protein kinase &#40;PKC&#41;, was originally developed as a cancer chemotherapeutic. It is being evaluated as a treatment for Alzheimer's disease by Blanchette Rockefeller Neurosciences Institute, the licensor to Neurotrope.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3261651-neurotrope-tumbles-alzheimers-data\" target=\"_blank\">Neurotrope tumbles on Alzheimer's data</a> (May 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279551\" data-linked=\"Neurotrope&#39;s mid-stage data on Alzheimer&#39;s candidate underwhelms investors; shares down 17%\" data-tweet=\"$NTRP - Neurotrope&#39;s mid-stage data on Alzheimer&#39;s candidate underwhelms investors; shares down 17% https://seekingalpha.com/news/3279551-neurotropes-mid-stage-data-on-alzheimers-candidate-underwhelms-investors-shares-down-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3279551-neurotropes-mid-stage-data-on-alzheimers-candidate-underwhelms-investors-shares-down-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279547\" data-ts=\"1500483990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATRX\" target=\"_blank\">ATRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279547-marina-biotech-up-11-on-smarticles-license-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marina Biotech up 11% on SMARTICLES license deal</a></h4><ul><li>Thinly traded nano cap Marina Biotech (<a href='https://seekingalpha.com/symbol/MRNA' title='Moderna, Inc.'>MRNA</a> <font color='green'>+10.6%</font>) perks up after the company <a href=\"https://seekingalpha.com/pr/16890977-marina-biotech-announces-license-agreement-smarticles-crn-platforms-antisense-dna\" target=\"_blank\">announced</a> that it has out-licensed its SMARTICLES platform for the delivery of antisense DNA therapeutics to Oncotelic, a first for the company.</li><li>Under the terms of the deal, Oncotelic will invest $250K in Marina via the purchase of common stock at $0.51/share. Subject to conditions, Marina may receive a commercial license fee via the sale of $500K of common shares to Oncotelic, in addition to sales-based milestones. Total potential sales milestones are capped at $90M. Additional financial terms are not disclosed.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3241149-marina-bio-inks-smarticles-license-agreement-unnamed-company-90m-milestones\" target=\"_blank\">Marina Bio inks SMARTICLES license agreement with unnamed company, up to $90M in milestones</a> (Feb. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279547\" data-linked=\"Marina Biotech up 11% on SMARTICLES license deal\" data-tweet=\"$ATRX - Marina Biotech up 11% on SMARTICLES license deal https://seekingalpha.com/news/3279547-marina-biotech-up-11-on-smarticles-license-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3279547-marina-biotech-up-11-on-smarticles-license-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279549\" data-ts=\"1500483512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGB\" target=\"_blank\">TGB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279549-taseko-mines-wins-b-c-approval-to-begin-work-new-prosperity-site\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Taseko Mines wins B.C. approval to begin work at New Prosperity site</a></h4><ul>     <li>Taseko Mines (<a href='https://seekingalpha.com/symbol/TGB' title='Taseko Mines Limited'>TGB</a> <font color='green'>+2.2%</font>) is up sharply after British Columbia's provincial government <a href=\"https://seekingalpha.com/pr/16889838-taseko-receives-approval-permit-development-work-new-prosperity\" target=\"_blank\">issues a work permit</a> authorizing exploration at  the site of the proposed New Prosperity copper-gold mining project, which twice has failed to obtain necessary federal approvals to proceed.</li>     <li>First Nations leaders <a href=\"http://www.miningweekly.com/article/taseko-gets-multiyear-now-permit-for-contentious-new-prosperity-mine-2017-07-19\" target=\"_blank\">harshly criticized</a> the permit, saying  B.C. \"disregarded the immense record showing the importance of this area for our culture and approved extensive ground disturbance for a mine that cannot lawfully be built.&rdquo;</li><li>TGB claims New Prosperity will create $12.7B of provincial GDP and increase provincial  revenues by more than $4B and federal revenues by at least $12B during its life.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3279549\" data-linked=\"Taseko Mines wins B.C. approval to begin work at New Prosperity site\" data-tweet=\"$TGB - Taseko Mines wins B.C. approval to begin work at New Prosperity site https://seekingalpha.com/news/3279549-taseko-mines-wins-b-c-approval-to-begin-work-new-prosperity-site?source=tweet\" data-url=\"https://seekingalpha.com/news/3279549-taseko-mines-wins-b-c-approval-to-begin-work-new-prosperity-site\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279545\" data-ts=\"1500482914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279545-vertex-shares-still-headroom-wsj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertex shares still have headroom - WSJ</a></h4><ul><li>The Wall Street Journal <a href=\"https://www.wsj.com/articles/vertex-shares-havent-hit-their-apex-1500477563\" target=\"_blank\">reports </a>that the rally in Vertex Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+21%</font>) is far from over, saying analysts' projections are high, but not unrealistic, despite an average expectation of almost $6B in revenue by 2022, about 2.5x this year's forecast of $2.2B.</li><li>The company's legacy cystic fibrosis &#40;CF&#41; drugs only treat ~half of CF sufferers. The triplet therapy, expected to be approved in 2020, will expand the treatable population to 90%.</li><li>Another upside benefit from the positive data may be improved patient adherence to treatment regimens. For example, slower-than-expected refills of Orkambi (lumacaftor/ivacaftor) have constrained financial results in the past.</li><li>CF patients will need treatment on an ongoing basis which should produce robust and consistent sales and cash flow.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279545\" data-linked=\"Vertex shares still have headroom - WSJ\" data-tweet=\"$VRTX - Vertex shares still have headroom - WSJ https://seekingalpha.com/news/3279545-vertex-shares-still-headroom-wsj?source=tweet\" data-url=\"https://seekingalpha.com/news/3279545-vertex-shares-still-headroom-wsj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279546\" data-ts=\"1500482767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279546-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+126%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/SMRT' title='Stein Mart, Inc.'>SMRT</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/SNI' title='Scripps Networks Interactive, Inc.'>SNI</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='red'>-40%</font>. <a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279546\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$AEZS $XCO $MYSZ - Midday Gainers / Losers https://seekingalpha.com/news/3279546-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3279546-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279542\" data-ts=\"1500481403\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279542-better-days-ahead-for-csx-analyst-says-in-keeping-faith\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Better days ahead for CSX, analyst says in keeping the faith</a></h4><ul>     <li>CSX (<a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> <font color='red'>-6.3%</font>) plunges more than 6% despite beating <a href=\"https://seekingalpha.com/news/3279351-csx-now-minus-4-percent-full-year-guidance-disappoints-analysts\" target=\"_blank\">Q2 earnings</a> forecasts, but Barclays analyst Brandon Oglenski says investors may be <a href=\"http://www.barrons.com/articles/why-csx-is-tanking-1500478597\" target=\"_blank\">overreacting</a> even though the Q2 beat really was a miss.</li>     <li>CSX reported Q2 adjusted EPS of $0.64, but after accounting for $58M in liquidated damages, a $55M property judgement and $10M of impairments, Oglenski thinks the quarter shakes out closer to $0.57.</li>     <li>\"Nonetheless, margin expansion is evident and we expect momentum in cost reduction as the company progresses toward a 'precision railroad' model, driving significant long-term value from current levels,\" the analyst writes.</li>     <li>\"Given clear improvement in margins and our confidence in material cost reduction opportunities looking forward, we continue to model nearly $4 in earnings for CSX by 2020, or 73% above our current year forecast,\" Oglenski says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279542\" data-linked=\"Better days ahead for CSX, analyst says in keeping the faith\" data-tweet=\"$CSX - Better days ahead for CSX, analyst says in keeping the faith https://seekingalpha.com/news/3279542-better-days-ahead-for-csx-analyst-says-in-keeping-faith?source=tweet\" data-url=\"https://seekingalpha.com/news/3279542-better-days-ahead-for-csx-analyst-says-in-keeping-faith\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279538\" data-ts=\"1500480035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279538-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SPAR' title='Spartan Motors, Inc.'>SPAR</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MKC' title='McCormick & Company, Inc.'>MKC</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279538\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$FIZZ $SPAR $ADOM - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3279538-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3279538-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279535\" data-ts=\"1500479784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCEHY\" target=\"_blank\">TCEHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279535-tencentplus-3_7-wechat-benefit-from-whatsapps-china-hurdles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tencent +3.7% as WeChat could benefit from WhatsApp&#39;s China hurdles</a></h4><ul>   <li>Tencent (<a href='https://seekingalpha.com/symbol/TCEHY' title='Tencent Holding Ltd. ADR'>OTCPK:TCEHY</a>) is <font color='green'>up 3.7%</font> on OTC markets and closed <font color='green'>up 3.9%</font> to its all-time high in high-volume Hong Kong trading amid expectations that its WeChat could benefit from a <a href=\"http://asia.nikkei.com/Business/AC/Tencent-shares-gain-as-China-blocks-WhatsApp\" target=\"_blank\">partial block</a> that China is putting on WhatsApp (<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color='green'>+1.5%</font>).</li>    <li>A partial blockage of WhatsApp would mean censorship touching the only major Facebook product that wasn't already banned in China (along with other international messaging apps).</li>    <li>A boost in censorship in China is being linked to the death of Nobel Peace Prize laureate Liu Xiaobo, amid concerns the government wants to block commemorations.</li>    <li>Tencent and Fubon Financial Holding are also establishing a joint insurance venture in Shenzhen, Nikkei notes.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279518-chinese-government-tells-tencent-baidu-improve-censorship\" target=\"_blank\">Chinese government tells Tencent, Baidu to improve censorship</a> (Jul. 19 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279535\" data-linked=\"Tencent +3.7% as WeChat could benefit from WhatsApp&#39;s China hurdles\" data-tweet=\"$TCEHY $TCEHY $FB - Tencent +3.7% as WeChat could benefit from WhatsApp&#39;s China hurdles https://seekingalpha.com/news/3279535-tencentplus-3_7-wechat-benefit-from-whatsapps-china-hurdles?source=tweet\" data-url=\"https://seekingalpha.com/news/3279535-tencentplus-3_7-wechat-benefit-from-whatsapps-china-hurdles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279532\" data-ts=\"1500479362\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DARE\" target=\"_blank\">DARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279532-dar-now-majority-owner-of-cerulean-after-completing-stock-transactions-cerulean-up-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dar now majority owner of Cerulean after completing stock transactions; Cerulean up 24%</a></h4><ul><li>Cerulean Pharma (CERU <font color='green'>+23.6%</font>) and Dar&eacute; Bioscience Operations have <a href=\"https://seekingalpha.com/pr/16890941-cerulean-pharma-dare-bioscience-announce-closing-new-stock-symbol-dare\" target=\"_blank\">completed</a> the stock transactions stipulated in their March 2017 agreement. Dar&eacute; stockholders are now the majority owners of Cerulean, with a 51% stake.</li><li>The combined firm will do business as Dar&eacute; Bioscience, Inc. starting tomorrow. It will also execute a 1:10 reverse split of its common stock tomorrow.</li><li>The new stock symbol will be \"DARE.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252183-cerulean-sells-assets-lays-staff-dare-bio-becomes-majority-owner-shares-plummet-62-percent\" target=\"_blank\">Cerulean sells assets, lays off staff as Dar&eacute; Bio becomes majority owner; shares plummet 62% premarket</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279532\" data-linked=\"Dar now majority owner of Cerulean after completing stock transactions; Cerulean up 24%\" data-tweet=\"$DARE - Dar now majority owner of Cerulean after completing stock transactions; Cerulean up 24% https://seekingalpha.com/news/3279532-dar-now-majority-owner-of-cerulean-after-completing-stock-transactions-cerulean-up-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3279532-dar-now-majority-owner-of-cerulean-after-completing-stock-transactions-cerulean-up-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279529\" data-ts=\"1500478449\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279529-ubs-bucks-vertex-upgrade-bandwagon-downgrades-to-neutral-174-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS bucks the Vertex upgrade bandwagon, downgrades to Neutral with $174 price target</a></h4><ul><li>UBS shuns the scrum of giddy sell-side shops who upgraded Vertex Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+22.3%</font>) after it reported positive results on its triplet therapy for cystic fibrosis &#40;CF&#41;.</li><li>Analyst Carter Gould <a href=\"https://www.streetinsider.com/Analyst+Comments/UBS+Downgrades+Vertex+%28VRTX%29+to+Neutral/13110761.html\" target=\"_blank\">raised his price target</a> on the stock to $174 (7% upside) from $135, but downgraded it to Neutral saying CF is nearing full valuation. He adds that the company's CF franchise could hit $8B in sales by the end of 2020, translating into $160/share. HIs $174 target includes the pipeline, platform and cash.</li><li>EPS estimates for 2017 and 2018 are $1.75 and $3.61, respectively.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279529\" data-linked=\"UBS bucks the Vertex upgrade bandwagon, downgrades to Neutral with $174 price target\" data-tweet=\"$VRTX - UBS bucks the Vertex upgrade bandwagon, downgrades to Neutral with $174 price target https://seekingalpha.com/news/3279529-ubs-bucks-vertex-upgrade-bandwagon-downgrades-to-neutral-174-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3279529-ubs-bucks-vertex-upgrade-bandwagon-downgrades-to-neutral-174-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279496\" data-ts=\"1500476436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279496-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+84%</font>. <a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='red'>-40%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/LAKE' title='Lakeland Industries, Inc.'>LAKE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279496\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$AEZS $VRTX $AVEO - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3279496-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3279496-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279512\" data-ts=\"1500475218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWW\" target=\"_blank\">GWW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279512-grainger-cfo-jardin-to-resign-effective-year-end\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Grainger CFO Jardin to resign, effective at year-end</a></h4><ul>     <li>Grainger (<a href='https://seekingalpha.com/symbol/GWW' title='W.W. Grainger, Inc.'>GWW</a> <font color='red'>-6.1%</font>) discloses the <a href=\"https://seekingalpha.com/filing/3628712\" target=\"_blank\">resignation</a> of CFO&nbsp;Ron Jadin, effective at the end of this year.</li>     <li>Jadin has served as CFO and Senior VP since 2008 and joined GWW in 1998 after 15 years at GE.</li>     <li>Shares are sharply lower after beating <a href=\"https://seekingalpha.com/news/3279447-w-w-graingers-q2\" target=\"_blank\">Q2 earnings</a> expectations and reaffirming FY 2017 guidance, but <a href=\"http://www.marketwatch.com/story/ww-grainger-cfo-to-retire-profit-falls-2017-07-19-104851720\" target=\"_blank\">profit fell 43%</a> and U.S. sales rose just 1% Y/Y.</li>     <li>Wells Fargo reiterates a <a href=\"http://www.barrons.com/articles/w-w-grainger-tumbles-despite-upbeat-q2-earnings-1500474298\" target=\"_blank\">Market Perform rating</a> on the stock, saying that while Q2 sales improved, no clear trends are emerging.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279512\" data-linked=\"Grainger CFO Jardin to resign, effective at year-end\" data-tweet=\"$GWW - Grainger CFO Jardin to resign, effective at year-end https://seekingalpha.com/news/3279512-grainger-cfo-jardin-to-resign-effective-year-end?source=tweet\" data-url=\"https://seekingalpha.com/news/3279512-grainger-cfo-jardin-to-resign-effective-year-end\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279511\" data-ts=\"1500475144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRMN\" target=\"_blank\">GRMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279511-garminplus-2_4-longbow-upgrades-seeing-return-to-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Garmin +2.4% as Longbow upgrades, seeing return to growth</a></h4><ul>   <li>Garmin (NASDAQ:<a href='https://seekingalpha.com/symbol/GRMN' title='Garmin Ltd.'>GRMN</a>) is <font color='green'>up 2.4%</font> after today's boost to Buy at Longbow on a bullish outlook for the company's outdoor, aviation and marine businesses.</li>    <li>The firm has a $60 price target, implying near-17% upside from today's higher price.</li>    <li>The company should get back to consistent profit growth in 2018, analyst Joe Wittine says, and the stock is a little undervalued compared to \"other low-growth tech peers.\" (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279511\" data-linked=\"Garmin +2.4% as Longbow upgrades, seeing return to growth\" data-tweet=\"$GRMN - Garmin +2.4% as Longbow upgrades, seeing return to growth https://seekingalpha.com/news/3279511-garminplus-2_4-longbow-upgrades-seeing-return-to-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3279511-garminplus-2_4-longbow-upgrades-seeing-return-to-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279509\" data-ts=\"1500474640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279509-crude-futures-rise-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures rise further post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>-4.7M</strong> barrels vs. -3.2M consensus, -7.6M last week.</li><li>Gasoline <strong>-4.4M</strong> barrels vs. -0.7M consensus, -1.6M last week.</li><li>Distillates -<strong>2.1M</strong> vs. +1.2M consensus, +3.1M last week.</li><li>Futures&nbsp;<font color='green'>+0.54%</font>&nbsp;to $46.65.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3279509\" data-linked=\"Crude futures rise further post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures rise further post inventory data https://seekingalpha.com/news/3279509-crude-futures-rise-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3279509-crude-futures-rise-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>159&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279507\" data-ts=\"1500474399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279507-jd-com-vipshop-deny-reports-of-merger-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com, Vipshop deny reports of merger talks</a></h4><ul>   <li>JD.com (<a href=\"http://seekingalpha.com/symbol/JD\" target=\"_blank\">JD</a> <font color='green'>+0.5%</font>) and Vipshop (<a href=\"http://seekingalpha.com/symbol/VIPS\" target=\"_blank\">VIPS</a> <font color='green'>+3.3%</font>) opened with gains in U.S. trading following chatter about merger talks, though each is denying the talks to the <i>21st Century Business Herald.</i></li>    <li>The report is \"pure rumor,\" a Vipshop exec says.</li>    <li>A combination would create one of the largest e-commerce companies in China, adding to JD.com's $63B market cap.</li>    <li>JD.com <font color='green'>rose 3.3%</font> in U.S. trade yesterday, while Vipshop <font color='green'>gained 3.8%</font> that day.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279507\" data-linked=\"JD.com, Vipshop deny reports of merger talks\" data-tweet=\"$JD $JD $VIPS - JD.com, Vipshop deny reports of merger talks https://seekingalpha.com/news/3279507-jd-com-vipshop-deny-reports-of-merger-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3279507-jd-com-vipshop-deny-reports-of-merger-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279506\" data-ts=\"1500474304\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRS\" target=\"_blank\">NTRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279506-northern-trust-down-6-after-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northern Trust down more than 6% after earnings miss</a></h4><ul><li>Excluding items, Q2 EPS of $1.18 was up from $1.07 a year ago, but missed expectations for $1.23.</li><li>Total assets under custody/administration of $9.3T up 15% Y/Y; AUM of $1T up 14%.</li><li>Noninterest income of $979.7B down 4% Y/Y. Net interest income of $350.4M up 14%; NIM of 1.28% up 12 basis points from a year ago, but fell seven basis points from Q1 - company notes an unfavorable mix shift in earning assets.</li><li>Noninterest expense of $937.4M up 1% Y/Y.</li><li>CET1 ratio of 13.3% (advanced approach), 12.1% standardized approach.</li><li><a href=\"https://www.northerntrust.com/financialreleases\" target=\"_blank\">Conference call at noon ET</a></li><li><a href=\"https://seekingalpha.com/article/4088686-northern-trust-corporation-2017-q2-results-earnings-call-slides\" target=\"_blank\">Presentation slides</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3279424-northern-trust-misses-0_11-revenue-line\" target=\"_blank\">Northern Trust misses by $0.11,  revenue in-line</a> (July 19)</li><li><a href='https://seekingalpha.com/symbol/NTRS' title='Northern Trust Corporation'>NTRS</a>&nbsp;<font color='red'>-6.4%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3279506\" data-linked=\"Northern Trust down more than 6% after earnings miss\" data-tweet=\"$NTRS - Northern Trust down more than 6% after earnings miss https://seekingalpha.com/news/3279506-northern-trust-down-6-after-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3279506-northern-trust-down-6-after-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279504\" data-ts=\"1500473646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHCT\" target=\"_blank\">CHCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279504-community-healthcare-trust-down-6-on-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Community Healthcare Trust down 6% on share sale</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/pr/16889873-community-healthcare-trust-incorporated-announces-launch-public-offering-common-stock\" target=\"_blank\">last night launched</a> a secondary offering of 4.25M shares with underwriter greenshoe of 637.5K shares. There's no word yet on pricing.</li><li><a href='https://seekingalpha.com/symbol/CHCT' title='Community Healthcare Trust'>CHCT</a>&nbsp;<font color='red'>-6.2%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3279504\" data-linked=\"Community Healthcare Trust down 6% on share sale\" data-tweet=\"$CHCT - Community Healthcare Trust down 6% on share sale https://seekingalpha.com/news/3279504-community-healthcare-trust-down-6-on-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3279504-community-healthcare-trust-down-6-on-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279501\" data-ts=\"1500473088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADTN\" target=\"_blank\">ADTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279501-adtranplus-9_3-after-record-revenue-drives-q2-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adtran +9.3% after record revenue drives Q2 beat</a></h4><ul>   <li>Communications equipment provider Adtran (NASDAQ:<a href='https://seekingalpha.com/symbol/ADTN' title='ADTRAN, Inc.'>ADTN</a>) has <font color='green'>gained 9.3%</font> after <a href=\"https://seekingalpha.com/news/3279367-adtran-beats-0_11-beats-revenue\" target=\"_blank\">Q2 earnings</a> again included record revenue, again driven by ultra-broadband solutions.</li>    <li>\"We continue to be at the forefront of several inflection points of innovation in the market, including next generation optical access, services transformation and Software Defined Access (SD-Access),\" says CEO Tom Stanton.</li>    <li>Gross profit grew 7.2%, to $84.6M; net income was up 21% to $12.4M.</li>    <li>Sales breakout: Products, $155.5M (up 12.3%); Services, $29.1M (up 20.6%).</li>    <li>Cash and equivalents came to $88.8M, up from $79.9M as of Dec. 31.</li>    <li><a href=\"http://www.adtran.com/investor\" target=\"_blank\">Conference call</a> to come at 10:30 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16890099-adtran-inc-reports-record-results-second-quarter-2017-declares-quarterly-cash-dividend\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3279501\" data-linked=\"Adtran +9.3% after record revenue drives Q2 beat\" data-tweet=\"$ADTN - Adtran +9.3% after record revenue drives Q2 beat https://seekingalpha.com/news/3279501-adtranplus-9_3-after-record-revenue-drives-q2-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3279501-adtranplus-9_3-after-record-revenue-drives-q2-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279493\" data-ts=\"1500471884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCI\" target=\"_blank\">CCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279493-crown-castleminus-2_5-plans-financing-for-7_1b-lightower-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crown Castle -2.5% as it plans financing for $7.1B Lightower deal</a></h4><ul>   <li>Crown Castle International (NYSE:<a href='https://seekingalpha.com/symbol/CCI' title='Crown Castle International Corp.'>CCI</a>) has opened <font color='red'>down 2.5%</font> in the wake of yesterday's <a href=\"https://seekingalpha.com/news/3279349-crown-castle-seals-7_1b-deal-lightower\" target=\"_blank\">$7.1B deal to nearly double its fiber network</a> via a purchase of Lightower (and a corresponding stock offering), and <a href=\"https://seekingalpha.com/news/3279389-crown-castle-beats-0_03-beats-revenue\" target=\"_blank\">earnings</a> where it beat consensus.</li>    <li>Along with the acquisition deal, Crown Castle is <a href=\"https://seekingalpha.com/pr/16890525-crown-castle-announces-proposed-public-offerings-common-stock-mandatory-convertible-preferred\" target=\"_blank\">launching offerings</a> of $3.25B worth of common stock and $1.5B in mandatory convertible preferred stock. Morgan Stanley, BofA Merrill Lynch and J.P. Morgan are joint book-runners.</li>    <li>In Q2, the company beat its previous guidance for net income, EBITDA and adjusted FFO. Site rental revenues rose about 8% ($42M from organic contribution, $40M in contribution from acquisitions, less $17M reduction in straight-line revenue).</li>    <li>\"As the wireless carriers turn to our infrastructure to improve and enhance their networks to meet what is expected to be a fourfold increase in mobile data demand by 2021, we believe there is a sustained runway of organic growth opportunities on our existing portfolio as well as opportunities for us to make accretive investments that enhance our long-term growth profile,\" says CEO Jay Brown.</li>    <li>For Q3, it's guiding to site rental revenues of $888M-$893M, EBITDA of $600M-$605M (vs. consensus for $612.5M), and adjusted FFO of $447M-$452M (vs. consensus for $464.4M). For the full year, it's forecasting site rental revenues of $3.504B-$3.529B, EBITDA of $2.389B-$2.414B (vs. consensus for $2.406B) and adjusted FFO of $1.813B-$1.838B (vs. $1.829B expected).</li>    <li><a href=\"https://seekingalpha.com/pr/16890178-crown-castle-reports-second-quarter-2017-results-updates-outlook-full-year-2017\" target=\"_blank\">Earnings Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3279493\" data-linked=\"Crown Castle -2.5% as it plans financing for $7.1B Lightower deal\" data-tweet=\"$CCI - Crown Castle -2.5% as it plans financing for $7.1B Lightower deal https://seekingalpha.com/news/3279493-crown-castleminus-2_5-plans-financing-for-7_1b-lightower-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3279493-crown-castleminus-2_5-plans-financing-for-7_1b-lightower-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279486\" data-ts=\"1500470781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EKSO\" target=\"_blank\">EKSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279486-ekso-initiates-34m-rights-offering-shares-slip-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ekso initiates $34M rights offering; shares slip 14% premarket</a></h4><ul><li>Nano cap Ekso Bionics (NASDAQ:<a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a>) is down&nbsp;<font color='red'>14%</font>&nbsp;premarket on higher-than-average volume in response to its <a href=\"https://seekingalpha.com/pr/16890703-ekso-bionics-announces-proposed-34-million-rights-offering-committed-investment-puissance\" target=\"_blank\">proposed rights offering</a> to shareholders and certain warrant holders.</li><li>The company plans to execute a pro rata distribution of non-transferable subscription rights to purchase up to 34M shares of common stock at $1.00 per share. The offering will commence in August.</li><li>Institutional investor Puissance Capital Management has committed to buy all unsubscribed shares subject to a 40% cap on its potential stake.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279486\" data-linked=\"Ekso initiates $34M rights offering; shares slip 14% premarket\" data-tweet=\"$EKSO - Ekso initiates $34M rights offering; shares slip 14% premarket https://seekingalpha.com/news/3279486-ekso-initiates-34m-rights-offering-shares-slip-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279486-ekso-initiates-34m-rights-offering-shares-slip-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279485\" data-ts=\"1500470692\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALSK\" target=\"_blank\">ALSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279485-alaska-communicationsplus-16_3-bell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alaska Communications +16.3% before the bell</a></h4><ul>   <li>Alaska Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ALSK' title='Alaska Communications Systems Group, Inc.'>ALSK</a>) is <font color='green'>up 16.3%</font> premarket, building off a late-day gain of 4.6% yesterday.</li>    <li>After volume yesterday exceeded a daily average of around 70,600 shares, nearly 100,000 have traded in premarket today.</li>    <li>The company <a href=\"https://seekingalpha.com/filing/3628459\" target=\"_blank\">filed a Form 4</a> yesterday noting that Michael Todd, the company's senior VP, Consumer Market, had disposed of 5,000 shares (nearly $11,000 worth).</li>    <li>Shares are <font color='green'>up 38.4%</font> YTD.</li>    <li>The company's set to report quarterly financial results before the opening bell Aug. 3.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279485\" data-linked=\"Alaska Communications +16.3% before the bell\" data-tweet=\"$ALSK - Alaska Communications +16.3% before the bell https://seekingalpha.com/news/3279485-alaska-communicationsplus-16_3-bell?source=tweet\" data-url=\"https://seekingalpha.com/news/3279485-alaska-communicationsplus-16_3-bell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279482\" data-ts=\"1500470111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYCC\" target=\"_blank\">CYCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279482-cyclacel-prices-equity-offering-shares-down-36-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cyclacel prices equity offering; shares down 36% premarket</a></h4><ul><li>Cyclacel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a>) plummets&nbsp;<font color='red'>36%</font>&nbsp;premarket on robust volume in response to the <a href=\"https://seekingalpha.com/pr/16890490-cyclacel-announces-pricing-13_2-million-underwritten-public-offering\" target=\"_blank\">pricing </a>of its public offering of Units.</li><li>Each Class A Unit, consisting of one share of common stock and one warrant to purchase one share of common at $2.00, will be offered at $2.00/Unit.</li><li>Each Class B Unit, consisting of one share of preferred stock (convertible into 500 common shares) and warrants to purchase 500 common shares at $2.00, will be offered at $1,000/Unit.</li><li>Closing date is July 21.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279482\" data-linked=\"Cyclacel prices equity offering; shares down 36% premarket\" data-tweet=\"$CYCC - Cyclacel prices equity offering; shares down 36% premarket https://seekingalpha.com/news/3279482-cyclacel-prices-equity-offering-shares-down-36-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279482-cyclacel-prices-equity-offering-shares-down-36-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279481\" data-ts=\"1500470096\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279481-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+46%&nbsp;</font>on FDA <a href=\"https://seekingalpha.com/news/3279418-fda-accepts-aeternas-resubmitted-marketing-application-macrilen-action-date-december-30\" target=\"_blank\">accepting</a> Aeterna's resubmitted marketing application for Macrilen.</li><li><a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+26%</font>&nbsp;on sell-side <a href=\"https://seekingalpha.com/news/3279415-sell-siders-upgrade-vertex-positive-data-cf-triple-combo-shares-27-percent-premarket\" target=\"_blank\">updates</a> on the announcement of positive results from studies assessing its triple combo regimens for the treatment of certain cystic fibrosis patients.</li><li><a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+22%</font>.</li><li><a href='https://seekingalpha.com/symbol/SNI' title='Scripps Networks Interactive, Inc.'>SNI</a> <font color='green'>+14%</font>&nbsp;on potential <a href=\"https://seekingalpha.com/news/3279353-discovery-plus-9_4-percent-scripps-networks-plus-10_4-percent-report-merger-discussion\" target=\"_blank\">merger</a> talks with Discovery Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>).</li><li><a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+13%</font>.</li><li><a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a> <font color='green'>+7%</font>&nbsp;on potential <a href=\"https://seekingalpha.com/news/3279353-discovery-plus-9_4-percent-scripps-networks-plus-10_4-percent-report-merger-discussion\" target=\"_blank\">merger</a>&nbsp;talks with Scripps Network Interactive (NYSE:<a href='https://seekingalpha.com/symbol/SNI' title='Scripps Networks Interactive, Inc.'>SNI</a>).</li><li><a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279481\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$AEZS $VRTX $MYSZ - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3279481-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3279481-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279480\" data-ts=\"1500469861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOL\" target=\"_blank\">TOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279480-homebuilders-higher-after-strong-housing-starts-number\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Homebuilders higher after strong housing starts number</a></h4><ul><li>Housing starts in June rose 8.3% from May to a seasonally adjusted annualized rate of 1.215M vs. estimates of 1.155M. June's pace was also up 2.1% on a year-over-year basis.</li><li>Single-family starts of 849K were up 6.3% from May.</li><li>Building permits also topped expectations, rising 7.4% from May and 5.1% Y/Y.</li><li>The homebuilders look set for opening gains, with Toll Brothers (NYSE:<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers Inc.'>TOL</a>)&nbsp;<font color='green'>up 0.9%</font>, PulteGroup (NYSE:<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a>)&nbsp;<font color='green'>up 0.6%</font>, Lennar (NYSE:<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a>)&nbsp;<font color='green'>up 0.3%</font>, and D.R. Horton (NYSE:<a href='https://seekingalpha.com/symbol/DHI' title='D. R. Horton Inc.'>DHI</a>)&nbsp;<font color='green'>up 0.7%</font>&nbsp;premarket.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>, <a href='https://seekingalpha.com/symbol/XHB' title='SPDR Homebuilders ETF'>XHB</a></li><li><a href=\"https://www.census.gov/construction/nrc/pdf/newresconst.pdf\" target=\"_blank\">Full report</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3279454-housing-starts-impress-june\" target=\"_blank\">Housing starts impress in June</a> (July 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279480\" data-linked=\"Homebuilders higher after strong housing starts number\" data-tweet=\"$TOL $TOL $PHM - Homebuilders higher after strong housing starts number https://seekingalpha.com/news/3279480-homebuilders-higher-after-strong-housing-starts-number?source=tweet\" data-url=\"https://seekingalpha.com/news/3279480-homebuilders-higher-after-strong-housing-starts-number\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279478\" data-ts=\"1500469842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279478-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a>&nbsp;<font color='red'>-35%</font>&nbsp;on filing <a href=\"https://seekingalpha.com/news/3279446-cyclacel-readies-equity-offering-shares-27-percent-premarket\" target=\"_blank\">S-1</a> for a planned public offering of units.</li><li><a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a>&nbsp;<font color='red'>-24%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3279448-spherix-prices-stock-offering-2_00-shares-20-percent-premarket\" target=\"_blank\">pricing</a> common stock offering.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3279478\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CYCC $SPEX - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3279478-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3279478-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279476\" data-ts=\"1500469693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279476-cymabay-prices-stock-offering-6_50-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay prices stock offering at $6.50, shares ahead 2% premarket</a></h4><ul><li>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on robust volume after the company <a href=\"https://seekingalpha.com/pr/16890491-cymabay-announces-pricing-public-offering-common-stock\" target=\"_blank\">announced </a>that it has priced its public offering of 13M shares of common stock at $6.50 per share. Underwriters over-allotment is an additional 1.95M shares. Closing date is July 24.</li><li>Yesterday's close was $6.94.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279476\" data-linked=\"CymaBay prices stock offering at $6.50, shares ahead 2% premarket\" data-tweet=\"$CBAY - CymaBay prices stock offering at $6.50, shares ahead 2% premarket https://seekingalpha.com/news/3279476-cymabay-prices-stock-offering-6_50-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279476-cymabay-prices-stock-offering-6_50-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279470\" data-ts=\"1500469398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLPG\" target=\"_blank\">GLPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279470-vertex-pharmas-gain-is-galapagos-pain-down-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertex Pharma&#39;s gain is Galapagos&#39; pain, down 6% premarket</a></h4><ul><li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos'>GLPG</a>) is under modest pressure premarket, down&nbsp;<font color='red'>6%</font>&nbsp;on increased volume on the heels of promising results from Vertex Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) triple combination regimen in cystic fibrosis &#40;CF&#41;.</li><li>Galapagos is also betting big in CF with triple combo regimens (GLPG3067/'2222/'2737 and '3067/'2222/'3221) in early-stage development.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279313-vertex-pharmas-triple-combo-regimens-show-positive-effect-treatment-resistant-cf-patients\" target=\"_blank\">Vertex Pharma's triple combo regimens show positive effect in treatment-resistant CF patients; shares ahead 24% after hours</a> (July 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279470\" data-linked=\"Vertex Pharma&#39;s gain is Galapagos&#39; pain, down 6% premarket\" data-tweet=\"$GLPG $GLPG $VRTX - Vertex Pharma&#39;s gain is Galapagos&#39; pain, down 6% premarket https://seekingalpha.com/news/3279470-vertex-pharmas-gain-is-galapagos-pain-down-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279470-vertex-pharmas-gain-is-galapagos-pain-down-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279461\" data-ts=\"1500468570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279461-dryshipsminus-30-on-latest-reverse-split-fifth-this-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DryShips -30% on latest reverse split, its fifth this year</a></h4><ul><li>DryShips (NASDAQ:<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>) <font color='red'>-30.3%</font> premarket after announcing a <a href=\"https://seekingalpha.com/pr/16889897-dryships-inc-announces-reverse-stock-split\" target=\"_blank\">1-for-7 reverse split</a>, the company's fifth reverse split this year and the eighth since early 2016.</li><li>The move comes despite more than 10 law firms announcing <a href=\"http://splash247.com/seven-more-firms-file-class-action-law-suits-against-dryships/\" target=\"_blank\">class action lawsuits since last Friday</a>, alleging violations of U.S. securities laws.</li><li>DRYS says the latest reverse split will take effect at the open on July 21, reducing the number of issued and outstanding common shares to ~5.2M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279461\" data-linked=\"DryShips -30% on latest reverse split, its fifth this year\" data-tweet=\"$DRYS - DryShips -30% on latest reverse split, its fifth this year https://seekingalpha.com/news/3279461-dryshipsminus-30-on-latest-reverse-split-fifth-this-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3279461-dryshipsminus-30-on-latest-reverse-split-fifth-this-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279451\" data-ts=\"1500466812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSLR\" target=\"_blank\">FSLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279451-first-solar-ja-solar-jump-johnson-upgrades-says-earnings-will-dazzle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First Solar, JA Solar jump as Johnson upgrades, says earnings will &quot;dazzle&quot;</a></h4><ul>     <li>First Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a>) <font color='green'>+3.2%</font> and JA&nbsp;Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/JASO' title='JA Solar Holdings, Co., Ltd.'>JASO</a>)&nbsp;<font color='green'>+3.5%</font> premarket after outspoken solar bear Gordon Johnson at Axiom Capital assumes a positive near-term bias on the sector and  upgrades the two stocks ahead of earnings.</li>     <li>Johnson sees consensus Q2 estimates rising with potential for material  upside to Q3 estimates given higher U.S. prices and module stockpiling  by U.S. solar independent power providers.</li><li>FSLR is upgraded to Buy from Hold with a $51 price target, as  Johnson says his checks suggest the company has delayed its transition to Series 6 technology,  instead running Series 4 production lines longer to accommodate Section  201-based demand.</li><li>JASO is upgraded to Hold with a $7 target, although Johnson says upside is capped given the $9.69 take private offer from its CEO.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/TAN' title='Invesco Solar Portfolio ETF'>TAN</a>, <a href='https://seekingalpha.com/symbol/KWT' title='VanEck Vectors Solar Energy ETF'>KWT</a></li><li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279451\" data-linked=\"First Solar, JA Solar jump as Johnson upgrades, says earnings will &quot;dazzle&quot;\" data-tweet=\"$FSLR $FSLR $JASO - First Solar, JA Solar jump as Johnson upgrades, says earnings will &quot;dazzle&quot; https://seekingalpha.com/news/3279451-first-solar-ja-solar-jump-johnson-upgrades-says-earnings-will-dazzle?source=tweet\" data-url=\"https://seekingalpha.com/news/3279451-first-solar-ja-solar-jump-johnson-upgrades-says-earnings-will-dazzle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279448\" data-ts=\"1500466560\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPEX\" target=\"_blank\">SPEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279448-spherix-prices-stock-offering-2_00-shares-down-20-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spherix prices stock offering at $2.00; shares down 20% premarket</a></h4><ul><li>Nano cap Spherix (NASDAQ:<a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a>) slumps<font color='red'> 20%</font>&nbsp;premarket on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16890355-spherix-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering</a> of 1.25M shares of common stock at $2.00 per share. Underwriters over-allotment is an additional 187.5K shares. Closing date is July 24. Net proceeds should be ~$2.1M.</li><li>Yesterday's close was $2.67.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279448\" data-linked=\"Spherix prices stock offering at $2.00; shares down 20% premarket\" data-tweet=\"$SPEX - Spherix prices stock offering at $2.00; shares down 20% premarket https://seekingalpha.com/news/3279448-spherix-prices-stock-offering-2_00-shares-down-20-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279448-spherix-prices-stock-offering-2_00-shares-down-20-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279447\" data-ts=\"1500466381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWW\" target=\"_blank\">GWW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279447-on-w-w-graingers-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on W.W. Grainger&#39;s Q2</a></h4><ul>     <li>W.W. Grainger (NYSE:<a href='https://seekingalpha.com/symbol/GWW' title='W.W. Grainger, Inc.'>GWW</a>) reports sales rose 2% in <a href=\"https://seekingalpha.com/pr/16890421-grainger-reports-results-2017-second-quarter\" target=\"_blank\">Q2</a>, driven by a 7 percentage point increase from volume growth.</li>     <li>U.S. business sales up 1% to $2B, driven by a 5 percentage point increase from volume and 1 percentage point from intercompany sales.</li>     <li>Canada business sales fell 3% to $189.11M.</li>     <li>Other businesses sales increased 11% to $526.56M.</li>     <li>Gross margin rate squeezed 80 bps to 39.8%</li>     <li>Adjusted operating margin rate declined 140 bps to 11.2%.</li>     <li><b>FY2017 Guidance</b>:&nbsp;Sales: +1% to +4%; Diluted EPS: $10 to $11.30; Tax rate: 35% to 36%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3279447\" data-linked=\"More on W.W. Grainger&#39;s Q2\" data-tweet=\"$GWW - More on W.W. Grainger&#39;s Q2 https://seekingalpha.com/news/3279447-on-w-w-graingers-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3279447-on-w-w-graingers-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279446\" data-ts=\"1500466013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYCC\" target=\"_blank\">CYCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279446-cyclacel-readies-equity-offering-shares-down-27-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cyclacel readies equity offering; shares down 27% premarket</a></h4><ul><li>Thinly traded nano cap Cyclacel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a>) slumps&nbsp;<font color='red'>27%&nbsp;</font>premarket on robust volume in response to the filing of an <a href=\"https://seekingalpha.com/filing/3626453\" target=\"_blank\">S-1</a> for a planned public offering of Units.</li><li>The company intends to offer 667,476 Class A Units and 8,250 Class B Units. Each Class A Unit consists of one share of common stock and one warrant to purchase one share of common.</li><li>Each Class B Unit, priced at $1,000, consists of one share of Series A Preferred Stock convertible into 242.72 shares of common at the initial conversion price and warrants to purchase the number of common shares equal to $1,000 divided by the conversion price.</li><li>Final pricing has yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279446\" data-linked=\"Cyclacel readies equity offering; shares down 27% premarket\" data-tweet=\"$CYCC - Cyclacel readies equity offering; shares down 27% premarket https://seekingalpha.com/news/3279446-cyclacel-readies-equity-offering-shares-down-27-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279446-cyclacel-readies-equity-offering-shares-down-27-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279441\" data-ts=\"1500465788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279441-chipotle-two-downgrades-one-upgrade-shares-down-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle: Two downgrades, one upgrade; shares down 1% premarket</a></h4><ul><li>Noting the combination of a reputational hit and a premium valuation, Wells Fargo's Jeff Farmer <a href=\"https://www.streetinsider.com/Analyst+Comments/Wells+Fargo+Downgrades+Chipotle+Mexican+Grill+%28CMG%29+to+Market+Perform%3B+Latest+Scare+Could+Slow+Recovery/13109403.html\" target=\"_blank\">downgrades</a> to Market Perform from Outperform.</li><li>Also downgrading from Outperform is BMO's&nbsp;Andrew Strelzik.</li><li>Defending the stock is Telsey's&nbsp;Robert Derrington. He upgrades to Outperform with $440 price target, suggesting&nbsp;<font color='green'>17% upside</font>.</li><li><a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a>&nbsp;<font color='red'>-1%</font>&nbsp;premarket to $371.</li></ul><div class=\"tiny-share-widget\" data-id=\"3279441\" data-linked=\"Chipotle: Two downgrades, one upgrade; shares down 1% premarket\" data-tweet=\"$CMG - Chipotle: Two downgrades, one upgrade; shares down 1% premarket https://seekingalpha.com/news/3279441-chipotle-two-downgrades-one-upgrade-shares-down-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279441-chipotle-two-downgrades-one-upgrade-shares-down-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279432\" data-ts=\"1500465154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGS\" target=\"_blank\">MDGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279432-medigus-expands-muse-distribution-deal-in-spain-shares-ahead-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medigus expands MUSE distribution deal in Spain; shares ahead 7% premarket</a></h4><ul> <li>Medigus (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a>) <a href=\"https://seekingalpha.com/pr/16890253-medigus-expands-global-commercial-availability-muse-distribution-agreement-izasa-hospital-s-l\" target=\"_blank\">announces</a> a distribution agreement in Spain with Izasa Hospital, S.L.U., a distributor of medical products in the hospital sector.</li><li>The five year commercialization agreement took effect July 1. Izasa Hospital, S.L.U. will be required to purchase a minimum of EUR 1.4M of <a href=\"http://www.medigus.com/healthcare-professional\" target=\"_blank\">Medigus Ultrasonic Surgical Endostapler</a> &#40;MUSE&#41; equipment over the course of the agreement. The MUSE system offers a minimally invasive solution for gastroesophageal reflux disease.</li><li>Shares are up&nbsp;<font color='green'>7%</font>&nbsp;premarket on modest volume.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3279432\" data-linked=\"Medigus expands MUSE distribution deal in Spain; shares ahead 7% premarket\" data-tweet=\"$MDGS - Medigus expands MUSE distribution deal in Spain; shares ahead 7% premarket https://seekingalpha.com/news/3279432-medigus-expands-muse-distribution-deal-in-spain-shares-ahead-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279432-medigus-expands-muse-distribution-deal-in-spain-shares-ahead-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279431\" data-ts=\"1500465021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PYPL\" target=\"_blank\">PYPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279431-paypal-down-1-suntrust-favors-visa-and-mastercard\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PayPal down more 1% as SunTrust favors Visa and Mastercard</a></h4><ul><li>Analyst Andrew Jeffrey rings the register on PayPal (NASDAQ:<a href='https://seekingalpha.com/symbol/PYPL' title='PayPal Holdings, Inc.'>PYPL</a>) after a 50% run higher this year. He downgrades to Hold from Buy, noting a less-favorable risk-reward.</li><li>Visa (NYSE:<a href='https://seekingalpha.com/symbol/V' title='Visa Inc.'>V</a>) and Mastercard (NYSE:<a href='https://seekingalpha.com/symbol/MA' title='Mastercard, Inc.'>MA</a>), he says, are \"more compelling secular growth vehicles\" with similar valuations and less risk than PayPal.</li><li>Source: Lily Katz at Bloomberg</li><li>PYPL<font color='red'> -1.25%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3279431\" data-linked=\"PayPal down more 1% as SunTrust favors Visa and Mastercard\" data-tweet=\"$PYPL $PYPL $V - PayPal down more 1% as SunTrust favors Visa and Mastercard https://seekingalpha.com/news/3279431-paypal-down-1-suntrust-favors-visa-and-mastercard?source=tweet\" data-url=\"https://seekingalpha.com/news/3279431-paypal-down-1-suntrust-favors-visa-and-mastercard\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279422\" data-ts=\"1500463676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MS\" target=\"_blank\">MS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279422-morgan-stanley-up-2_5-after-topping-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley up 2.5% after topping estimates</a></h4><ul><li>Q2 net income of $1.8B or $0.87 per share vs. $1.6B and $0.75 earned one year ago.</li><li>Institutional Securities pretax income of $1.4B vs. $1.5B a year ago. Revenue of $4.8B vs. $4.6B; investment banking revenue of $1.4B vs. $1.1B; sales and trading revenue of $3.2B vs. $3.3B, with fixed income sales of $1.2B vs. $1.3B - smaller decline than seen at rivals.</li><li>Wealth Management pretax income of $1.1B vs. $859M a year ago. Revenue of $4.2B vs. $3.8B. Pretax margin of 25%. Net interest income rises to $1B from $829M.</li><li>CET1 ratio of 16.6%. Tangible book value per share of $33.24.</li><li>$500M of stock repurchased during quarter. A new $5B plan began in Q3.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279407-morgan-stanley-beats-0_11-beats-revenue\" target=\"_blank\">Morgan Stanley beats by $0.11, beats on revenue</a> (July 19)</li><li><a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>&nbsp;<font color='green'>+2.55%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3279422\" data-linked=\"Morgan Stanley up 2.5% after topping estimates\" data-tweet=\"$MS - Morgan Stanley up 2.5% after topping estimates https://seekingalpha.com/news/3279422-morgan-stanley-up-2_5-after-topping-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3279422-morgan-stanley-up-2_5-after-topping-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279418\" data-ts=\"1500463008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEZS\" target=\"_blank\">AEZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279418-fda-accepts-aeternas-resubmitted-marketing-application-for-macrilen-action-date-december-30\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Aeterna&#39;s resubmitted marketing application for Macrilen, action date December 30; shares ahead 52% premarket</a></h4><ul><li>Thinly traded nano cap Aeterna Zentaris (NASDAQ:<a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a>) is up&nbsp;<font color='green'>52%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16890006-nda-macrilen-evaluation-growth-hormone-deficiency-adults-granted-december-30-2017-pdufa-date\" target=\"_blank\">announcement </a>that the FDA has accepted for review its resubmitted New Drug Application &#40;NDA&#41; seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults &#40;AGHD&#41;. The agency's action date &#40;PDUFA&#41; is December 30.</li><li>The company received a Complete Response Letter &#40;CRL&#41; in November 2014 citing the need for an additional clinical trial and the lack of data for determining whether patients were accurately diagnosed with AGHD.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2103255-aeterna-zentaris-slammed-after-fda-rejection\" target=\"_blank\">Aeterna Zentaris slammed after FDA rejection</a> (Nov. 6, 2014)</li><li>Previously: <a href=\"https://seekingalpha.com/news/2422136-aeterna-zentaris-to-conduct-new-phase-3-study-to-demonstrate-efficacy-of-macrilen\" target=\"_blank\">Aeterna Zentaris to conduct new Phase 3 study to demonstrate efficacy of Macrilen</a> (April 13, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279418\" data-linked=\"FDA accepts Aeterna&#39;s resubmitted marketing application for Macrilen, action date December 30; shares ahead 52% premarket\" data-tweet=\"$AEZS - FDA accepts Aeterna&#39;s resubmitted marketing application for Macrilen, action date December 30; shares ahead 52% premarket https://seekingalpha.com/news/3279418-fda-accepts-aeternas-resubmitted-marketing-application-for-macrilen-action-date-december-30?source=tweet\" data-url=\"https://seekingalpha.com/news/3279418-fda-accepts-aeternas-resubmitted-marketing-application-for-macrilen-action-date-december-30\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279415\" data-ts=\"1500462450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279415-sell-siders-upgrade-vertex-after-positive-data-on-cf-triple-combo-shares-up-27-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-siders upgrade Vertex after positive data on CF triple combo; shares up 27% premarket</a></h4><ul><li>On cue, sell-side shops announce upgrades on Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) on the heels of its announcement of positive results from studies assessing its triple combo regimens for the treatment of certain cystic fibrosis patients.</li><li>Raymond James: upgrade to Outperform from Market Perform.</li><li>Janney: upgrade to Buy.</li><li>Cowen: upgrade to Outperform from Market Perform with $200 (52% upside) price target.</li><li>Barclays: upgrade to Overweight from Equal Weight.</li><li>Shares are up&nbsp;<font color='green'>27%</font>&nbsp;premarket on modestly higher volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3279313-vertex-pharmas-triple-combo-regimens-show-positive-effect-treatment-resistant-cf-patients\" target=\"_blank\">Vertex Pharma's triple combo regimens show positive effect in treatment-resistant CF patients; shares ahead 24% after hours</a> (July 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3279415\" data-linked=\"Sell-siders upgrade Vertex after positive data on CF triple combo; shares up 27% premarket\" data-tweet=\"$VRTX - Sell-siders upgrade Vertex after positive data on CF triple combo; shares up 27% premarket https://seekingalpha.com/news/3279415-sell-siders-upgrade-vertex-after-positive-data-on-cf-triple-combo-shares-up-27-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3279415-sell-siders-upgrade-vertex-after-positive-data-on-cf-triple-combo-shares-up-27-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279408\" data-ts=\"1500461984\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBD\" target=\"_blank\">DBD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279408-diebold-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diebold beats by $0.02, beats on revenue</a></h4><ul><li>Diebold (NYSE:<a href='https://seekingalpha.com/symbol/DBD' title='Diebold Nixdorf'>DBD</a>): Q2 EPS of $0.08 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $1.13B (+94.8% Y/Y) <font color='green'>beats by $30M</font>.</li><li>Shares <font color='green'>+5.39%</font> PM.</li><li><a href='http://phx.corporate-ir.net/phoenix.zhtml?c=106584&p=quarterlyearnings'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279408\" data-linked=\"Diebold beats by $0.02, beats on revenue\" data-tweet=\"$DBD - Diebold beats by $0.02, beats on revenue https://seekingalpha.com/news/3279408-diebold-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3279408-diebold-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3279391\" data-ts=\"1500458467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASML\" target=\"_blank\">ASML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3279391-asml-holding-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ASML Holding reports Q2 results</a></h4><ul><li>ASML Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/ASML' title='ASML Holding N.V.'>ASML</a>): Q2 EPS of&nbsp;&euro;1.08</li><li>Revenue of&nbsp;&euro;2.1B (+20.7% Y/Y)</li><li>Shares <font color='green'>+3.36%</font> PM.</li><li><a href=\"https://staticwww.asml.com/doclib/investor/financial_results/2017/asml_20170719_USGAAP_2017_Q2.pdf\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3279391\" data-linked=\"ASML Holding reports Q2 results\" data-tweet=\"$ASML - ASML Holding reports Q2 results https://seekingalpha.com/news/3279391-asml-holding-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3279391-asml-holding-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:01 AM </div></div></li>","count":70,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}